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Abstract
Early diagnosis of hepatocellullar carcinoma (HCC) remains a challenge. The current practice of serum alpha-fetoprotein
(AFP) measurement is inadequate. Here we utilized a proteomic approach to identify novel serum biomarkers for
distinguishing HCC patients from non-cancer controls. We profiled the serum proteins in a group of 58 resectable HCC
patients and 11 non-HCC chronic hepatitis B (HBV) carrier samples from the Singapore General Hospital (SGH) using the
RayBioH L-Series 507 Antibody Array and found 113 serum markers that were significantly modulated between HCC and
control groups. Selected potential biomarkers from this list were quantified using a multiplex sandwich enzyme-linked
immunosorbent assay (ELISA) array in an expanded SGH cohort (126 resectable HCC patients and 115 non-HCC chronic HBV
carriers (NC group)), confirming that serum prolactin and monocyte chemoattractant protein-1 (MCP-1) were significantly
upregulated in HCC patients. This finding of serum MCP-1 elevation in HCC patients was validated in a separate cohort of
serum samples from the Mochtar Riady Institute for Nanotechnology, Indonesia (98 resectable HCC, 101 chronic hepatitis B
patients and 100 asymptomatic HBV/HCV carriers) by sandwich ELISA. MCP-1 and prolactin levels were found to correlate
with AFP, while MCP-1 also correlated with disease stage. Subsequent receiver operating characteristic (ROC) analysis of
AFP, prolactin and MCP-1 in the SGH cohort and comparing their area under the ROC curve (AUC) indicated that neither
prolactin nor MCP-1 on their own performed better than AFP. However, the combination of AFP+MCP-1 (AUC, 0.974) had
significantly superior discriminative ability than AFP alone (AUC, 0.942; p,0.001). In conclusion, prolactin and MCP-1 are
overexpressed in HCC and are conveniently quantifiable in patients’ sera by ELISA. MCP-1 appears to be a promising
complementary biomarker for HCC diagnosis and this MCP-1+AFP model should be further evaluated as potential
biomarker on a larger scale in patients at-risk of HCC.
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Introduction
Hepatocellullar carcinoma (HCC) is the sixth most common
cancer worldwide (fifth most common cancer in men and the
seventh in women) and the third leading cause of cancer deaths
worldwide, with East and South-East Asia carrying the largest
HCC burden [1,2]. Its increased incidence is attributable to an
increased prevalence of hepatitis B and C virus infections [2]. The
number of new cases per year worldwide is estimated to be
748,000 (10.8 per 100,000) [1]. The outcome of patients with
HCC is dismal and majority of patients present in the late stages
when therapy has modest benefit. Only about 30% of newly
diagnosed HCCs are detected in the early stages when potentially
curative treatment such as surgical resection or liver transplanta-
tion is feasible and 5-year survival rates range from 50–70% [3].
Patients with liver cirrhosis are at risk of developing HCC [4].
Chronic hepatitis B (HBV) and C (HCV) infections are associated
with about 70% and 20% of HCC in the Asian and African
populations respectively [2,4]. This provides an opportunity for
close surveillance and early diagnosis in an at-risk population for
which early detection may permit interventions that reduce
cancer-specific mortality [5]. The American Association for the
Study of Liver Disease guidelines recommended the use of
periodic examination of serum alpha-fetoprotein (AFP) levels
and abdominal ultrasound scans as the main screening tools for
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early detection of HCC in chronic liver disease patients, but the
accuracy and usefulness of these tests remain questionable [6]. At a
commonly adopted cut-off value of 20 ng/ml, AFP has a
sensitivity ranging from 49 to 71% and specificity from 49 to
86% in HCCs smaller than 5 cm [7–9]. Furthermore, it was also
found to exhibit no prognostication value in a group of patients
with cirrhosis with a single HCC of #3 cm in diameter [10].
Ultrasound scanning, on the other hand, has a sensitivity of 65 to
80% and a specificity of 90% when used as a screening tool.
However, its accuracy in nodular cirrhotic livers is not well defined
[11]. Hence, there is still a need to identify biomarkers that can
replace or complement AFP and ultrasound scanning for early
diagnosis of HCC.
To be clinically useful, a diagnostic biomarker should be easily
measured non-invasively in easily assessable body fluids such as
serum and urine. In HCC, serum AFP-L3 and Des-gamma-
carboxy prothrombin (DCP) are two of the most studied
alternative HCC tumor markers, and may be more effective than
AFP alone in differentiating HCC from non-malignant hepatop-
athy and predicting prognosis [12,13]. However, their superiority
in detecting early stage HCCs remain doubtful [14,15]. Trans-
forming growth factor-beta1 (TGF-b1) and serum vimentin have
also been proposed as potential biomarkers for small-sized HCC
tumors [16,17]. Serum SELDI-TOF proteomic signature, alone or
in combination with AFP marker, may also be a promising tool for
HCC screening in an at-risk population with liver cirrhosis due to
its high sensitivity and specificity [18]. In separate reports, serum
glypican-3 and human telomerase reverse transcriptase (hTERT)
mRNA were also found to be increased in patients with HCC
[19,20]. While Llovet JM et al demonstrated that a three-gene set
comprising glypican-3, LYVE1 (lymphatic vessel endothelial
hyaluronan receptor-1) and survivin was able to differentially
diagnose HCC from dysplastic nodule tissue with high accuracy
[21]. Recently, efforts by Jain et al showed methylation of the 59-
end of the glutathione S-transferase p 1 (GSTP1) gene promoter in
tissues as a potential HCC marker to identify HCC among the at-
risk hepatitis and cirrhosis patients [22]. Most recently, strong
evidence had been presented to show that serum Dickkopf-1
(DKK1) could be used as a complementary biomarker for AFP for
significantly superior diagnosis capability in detecting early HCC
than AFP alone [23]. However, more studies are needed to
validate these candidate HCC biomarkers and confirm their
predictive and/or prognostic values. We therefore participated in
the effort to identify novel HCC biomarkers that will improve the
diagnosis of early HCC over the current screening practice of
serum AFP measurements.
Enzyme-linked immunosorbent assay (ELISA)-based methods
are considered to be amongst the most robust platforms for
biomarker discovery and are known for their high degree of
sensitivity [24]. Recent advancement in protein array technology
has created a high-throughput platform for biomarker screening
by ELISA. In this study, we employed the Raybiotech L-Series
507 antibody array platform, a novel antibody array that
simultaneously detects 507 serum proteins, to identify potential
predictive markers for HCC [25]. Here, we report the identifica-
tion of two novel serum biomarkers, namely prolactin and
monocyte chemoattractant protein-1 (MCP-1) that were signifi-
cantly elevated in patients with resectable HCC compared to non-
HCC chronic hepatitis B (HBV) carriers. We also demonstrate
that one of these markers, MCP-1, may be complementary to AFP
to improve the diagnosis of HCC in at-risk patients.
Materials and Methods
Ethics Statement
All procedures for informed consent, data collection and privacy
protection were approved by the SingHealth Centralised Institu-
tional Review Board for the Singapore General Hospital (SGH)
cohort (approval number 2009/932/B for utilizing archived HCC
patient serum samples obtained from the SingHealth Tissue
Repository and number 2010/510/B for serum collection from
non-HCC HBV carriers) and by The Committee on Health
Research Ethics for the Mochtar Riady Institute for Nanotech-
nology (MRIN) cohort (approval number 003/MI/EC/2007). All
adult patients gave written informed consent prior to serum
collection. For the single HCC patient who was under 18 years of
age at the time of serum collection in the SGH cohort, written
consent was obtained from the legal guardian on behalf of the
patient.
Patients
From 2000 to 2011, serum from 126 patients with completely
resected HCC and 115 non-HCC chronic HBV carriers (NC
group) were collected from the Department of General Surgery
and the Department of Gastroenterology and Hepatology, SGH
respectively. All 126 HCC patients underwent hepatectomy in
SGH. The histology of the resected specimens confirmed the
diagnosis of HCC, and the size of tumors, presence or absence of
cirrhosis in non-cancerous tissues, were routinely reported by
pathologists. Table 1 summarizes the patient and tumor charac-
teristics. These HCC patients had either pathological stage I/II
HCC (S1 group, n = 93) or pathological stage III/IV HCC (S3
group, n = 33) according to AJCC Cancer Staging Manual 6th
edition published by the American Joint Committee on Cancer
(AJCC) [26]. The patients’ ages ranged from 15–86 years with a
median age of 64. Sixty-seven patients (53.2%) had HBV
infection, 9 (7.1%) had hepatitis C (HCV) infection, 1 (0.8%)
had both HBV and HCV infection, the remaining 49 (38.9%)
were hepatitis-negative. One hundred and twenty-four patients
had Child-Pugh class A liver function (98.4%) and the remaining 2
had Child-Pugh class B liver function. Most patients had Eastern
Cooperative Oncology Group (ECOG) performance status of 0–1
(91%) while 5 patients (9%) had ECOG performance status of 2.
Fifty-six patients (44.4%) demonstrated histological evidence of
liver cirrhosis. Thirty-six patients (28.6%) had tumor size less than
3 cm while 23 patients (18.3%) had tumor size of 10 cm or more.
The rest (53.1%) had tumor size of between 3 and 10 cm. In
addition, each patient’s Barcelona Clinic Liver Cancer (BCLC)
stage was calculated [27]. Most patients had BCLC stage A
(n = 82, 65.1%), 19 had BCLC stage B (15.1%), 24 had BCLC C
(19%) and 1 had BCLC D (0.8%). For the corresponding non-
HCC control group (NC group), all 115 patients had chronic HBV
infection. The patients’ ages ranged from 21–73 years with a
median age of 52. These patients represented the at-risk
population who were monitored by routine follow-up visits. All
of these patients had ECOG scores of 0, normal AFP levels
(,20 ng/ml) and Child-Pugh class A liver function. A follow up
visit six months after serum collection confirmed these HBV
carriers’ non-HCC status.
Serum samples from a separate, independent cohort of
Indonesian patients at various disease stages from Mochtar Riady
Institute for Nanotechnology (MRIN), Indonesia, were used for
further validation of serum MCP-1 levels. This cohort consisted of:
(1) HCC group (n = 98), (2) chronic viral hepatitis patients with
evidence of transaminitis (CH group, n = 101), and (3) asymp-
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tomatic hepatitis carriers (AC group, n = 100: 65 HBV +35 HCV
carriers).
Serum Protein Profiling
Soluble proteins in a subset of 58 HCC (39 from S1 group, 19
from S3 group) and 11 non-HCC control serum samples from the
SGH cohort were profiled using the RayBioH L-Series 507 Biotin
Label-based Antibody Array system (RayBiotech, GA, USA).
Briefly, proteins in the serum samples were biotinylated, followed
by spin filtering to remove excess biotin. The biotinylated samples
were dialyzed with PBS and added to the array membranes.
Biotinylated proteins captured by the membrane-bound antibodies
were detected by incubation with HRP-streptavidin and analysis
by a chemiluminescence imaging system. Normalization was
performed using the signal of internal controls on each protein
array chip. Quality control was performed with the removal of
proteins detected below the raw signal intensity of 50, which was
twice the maximum intensity of the negative control probes.
Significance testing was performed by t-Test and fold-change was
cut-off at 2.0.
Serum Protein Quantification
To validate data from the L Series 507 array analysis, selected
proteins from the list of significantly modulated serum protein
markers detected in the array analysis were quantified using
multiplex sandwich ELISA arrays (Custom Quantibody Array,
Raybiotech, GA, USA) according to the manufacturer’s instruc-
tions in the entire SGH cohort of 126 HCC patients (the 58
samples used in profiling array plus additional 68 samples) and in
115 non-HCC hepatitis B carriers (the 11 NC group samples used
in the profiling array plus additional 104 samples). All samples
were run in quadruplicates.
Serum MCP-1 levels in the MRIN cohort were analyzed in
duplicates by sandwich ELISA using a matched antibody pair and
recombinant human MCP-1 according to the manufacturer’s
instructions (RayBiotech, GA, USA). Optical density was mea-
sured using Microplate Imaging System (BioRad, CA, USA). A
four-parameter logistic (4-PL) curve-fit consisting of seven
standard concentrations was generated using Microplate Manager
5.2.1 software (BioRad). The lower limit of detection (LOD) for
each marker in the assays was determined based on the average
raw data of two sets of standard curves and from the average of
two negative controls and their standard deviation (by calculating
Average +2x Standard Deviation). Signal strengths below the
LOD for each biomarker in each assay were considered as
undetectable.
In the SGH cohort, serum AFP levels in the HCC patients were
measured by the SGH clinical laboratory prior to the patients
undergoing hepatectomy. AFP levels in the non-HCC hepatitis B
carriers were measured likewise as part of the blood tests
performed during routine follow-up visits.
Statistical Analysis
The serum biomarker levels in cancer patients and controls
were compared using Mann-Whitney U test. Correlation between
serum markers was assessed using Spearman’s rank correlation
coefficient (rho). The association between each serum marker and
various patient demographics and clinical parameters was assessed
using the Mann-Whitney U test. When more than two groups
were involved, the Kruskal-Wallis test was used.
Univariable logistic regression was carried out to evaluate the
effect of different serum makers on the development of HCC.
Recurrence-free survival (RFS) was defined as the time from date
of surgery to date of first relapse, or to the last follow up date for
censored cases, while overall survival (OS) was defined as the time
from date of diagnosis to date of death, or to the last follow up date
for censored cases. Kaplan-Meier survival curves were used to
estimate RFS and OS and log-rank test was used to assess if the
survival function between groups were different. The 95th
percentile of the non-HCC group values was rounded to the
nearest one decimal point and adopted as the upper limit of
normal (ULN) for each biomarker. The biomarkers were
dichotomized at their ULN values and survival functions
compared. Univariable Cox regression was carried out first to
evaluate the effect of individual factor on RFS and OS.
Subsequently, reduced model selection was carried out to select
a multivariable model using a backward stepdown by applying
stopping rule of the Akaike’s information criterion (AIC).
Proportional hazards assumptions were verified systematically for
all proposed models.
The area under the Receiver Operating Characteristic (ROC)
Curve was reported to evaluate the ability of the potential serum
Table 1. Demographics of patients (SGH cohort).
Characteristic HCC (n=126) NC (n=115)
n Frequency n Frequency
Gender
Female 30 23.8% 40 36.4%
Male 96 76.2% 70 63.6%
Hepatitis Infection
Hepatitis B 67 53.2% 115 100.0%
Hepatitis C 9 7.1% 0 0.0%
Hepatitis B+C 1 0.8% 0 0.0%
Non-Hepatitis 49 38.9% 0 0.0%
AFP
,20 ng/ml 57 47.5% 110 100.0%
$20 ng/ml 63 52.5% 0 –
Cirrhosis
No 70 55.6% – –
Yes 56 44.4% – –
Child-Pugh Score
A 124 98.4% 115 100%
B 2 1.6% – –
AJCC Stage
I 70 55.6% – –
II 23 18.3% – –
III 32 25.4% – –
IV 1 0.8% – –
BCLC Score
A 82 65.1% – –
B 19 15.1% – –
C 24 19% – –
D 1 0.8% – –
Tumour Size
Size #3 cm 36 28.6% – –
3 cm,Size ,10 cm 67 53.2% – –
Size $10 cm 23 18.3% – –
doi:10.1371/journal.pone.0068904.t001
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markers in discriminating HCC patients from the controls.
Multivariable logistic regression was performed to select the most
suitable diagnostic model using a combination of serum markers.
Clustering of these markers based on Spearman correlation was
performed to reduce the number of variables to be included in the
final model. Calibration plot was generated to explore the
performance characteristics of this model by means of boot-
strapping of 200 samples. Likelihood ratio testing of nested models
was performed to compare our final diagnostic model to the other
models including a subset of serum markers. An adequacy index
was used to quantify the percentage of the variation explained by a
subset of these predictors compared with the information
contained in the full set of predictors in our final diagnostic
model by means of log-likelihood.
All analyses were done using R 2.14.0 (http://www.R-project.
org) and STATA 11 (STATA Corporation, College Station, TX,
USA), and all tests were two-sided with a significance level of 0.05.
Results
Identification of Potential HCC Serum Markers
Using RayBioH L-Series 507 Antibody Array that simulta-
neously detects the levels of 507 proteins, we profiled the serum
proteins in a subset of 58 HCC patients (39 from S1 group, 19
from S3 group) and 11 non-HCC HBV carriers from the SGH
cohort to detect potential biomarkers for early detection of HCC.
By comparing the profiles of patients in the HCC groups to the
NC group, we identified distinct patterns that may be specific and
potentially predictive for HCC. 145 and 134 proteins were
significantly modulated between HBV carriers and the S1 and S3
groups of HCC patients respectively. Among these markers, we
found that 113 proteins were significantly and consistently up- or
down-modulated in both S1 and S3 groups relative to the NC
group. Several of these proteins are known to be associated with
chemotactic activities, immunomodulation, angiogenesis, cell
adhesion and tumor suppression (Table S1).
Marker Selection and Validation
We selected 5 proteins from the list of 113 potential markers for
further validation by ELISA quantification in the SGH cohort
using the Custom Quantibody Array, namely MCP-1, prolactin,
angiostatin, interferon gamma inducible T cell alpha chemoat-
tractant (I-TAC) and tissue inhibitor of metalloproteinases-4
(TIMP-4) that showed high fold changes and for which
quantification by the multiplex sandwich ELISA array was
possible. Consistent with the antibody array results, Mann-
Whitney U test showed that serum samples from HCC patients
(n = 126) had significantly higher levels of MCP-1 (med-
ian = 0.67 ng/ml; interquartile range, IQR, 0.37–1.14 ng/ml)
and prolactin (median = 66.54 ng/ml; IQR, 41.79–98.32 ng/ml)
compared to the NC group (n = 115) that had median values of
0.30 ng/ml (IQR, 0.24–0.37 ng/ml; p,0.001) and 15.85 ng/ml
(IQR, 7.0–46.58 ng/ml; p,0.001) respectively (Figure 1). Con-
centration differences of the remaining three markers were
insignificant and thus were excluded from subsequent analysis
(not shown).
To test the consistency of our observation that MCP-1 was
significantly elevated in HCC patients, we evaluated serum MCP-
1 levels in an independent cohort of Indonesian patient samples
consisting of sera obtained from 98 HCC patients, 101 chronic
hepatitis B patients with evidence of transaminitis (CH group) and
100 non-HCC HBV/HCV carriers (AC grouop). We performed
conventional sandwich ELISA to quantify serum MCP-1 levels
and observed significantly higher MCP-1 concentration in the
HCC patients (median = 0.47 ng/ml; IQR, 0.29–0.80 ng/ml)
relative to CH (median = 0.38 ng/ml; IQR, 0.17–0.75 ng/ml;
p = 0.026) and AC (median = 0.28 ng/ml; IQR, 0.16–0.55 ng/ml;
p,0.001) groups (Figure 1A). We also found that the difference in
median MCP-1 concentrations between the AC and CH groups
was statistically insignificant (increment of 0.1 ng/ml; p = 0.194).
Since the ELISA method used for assaying the MRIN cohort was
different from the method adopted for the SGH cohort, although
with the same underlying principle, we tested the sensitivity and
consistency between both methods by performing Mann-Whitney
U test to compare the MCP-1 levels detected in the non-HCC
hepatitis carrier reference groups of both cohorts. The resulting p-
value of 0.552 showed that the sensitivity of both ELISA methods
were comparable (Figure 1A).
In the SGH cohort, serum AFP level data was available for 110
of the NC group and 120 of the HCC patients. AFP levels were
,20 ng/ml in all of these non-HCC hepatitis B carriers. In the
HCC patients group, AFP level was elevated above 20 ng/ml in
52.5% of patients (63/120 patients, Table 1). The serum AFP
levels in HCC patients had a median value of 27 ng/ml (IQR,
1.8–31815 ng/ml) which was significantly higher than in the NC
group (median = 2.5 ng/ml; IQR, 1.1–4.8 ng/ml; p = 0.0001;
Figure 1C).
Correlation of Serum MCP-1 and Prolactin Levels with
AFP
Since serum AFP, MCP-1 and prolactin were significantly
elevated in HCC patients, we evaluated possible correlation
among these serum markers. We performed Spearman’s rank
correlation coefficient (rho) calculations on the entire cohort of
SGH samples collected (n = 241) and found significant positive
correlation between MCP-1 and AFP levels (rho = 0.7926,
p = 0.024) and a weaker correlation between prolactin and AFP
levels (rho = 0.6419, p = 0.043). Interestingly, a weak inverse
correlation was found between MCP-1 and prolactin
(rho =20.269, p = 0.002; Table 2).
Association of Serum MCP-1 and Prolactin Levels with
Various Patient Demographics and Disease
Characteristics
We also analyzed for effects of various clinical parameters on
serum MCP-1 and prolactin levels in the SGH cohort. We found
that serum levels of MCP-1 was significantly higher in patients
with late stages and higher BCLC scores (p = 0.0005 and
p,0.0001 respectively). Serum prolactin level, however, was not
affected by these parameters (p = 0.2869 and p = 0.2145 respec-
tively). Other clinicopathologic parameters, such as gender, viral
hepatitis status and liver cirrhosis did not affect the serum levels of
these two markers. We also evaluated the impact of hepatitis using
serum aspartate transaminase (AST) and alanine transaminase
(ALT) as indices for injury to hepatocytes. We found no
association between MCP-1 and prolactin levels with liver function
status (Table S2).
Association of Clinicopathological Parameters and Serum
Markers with RFS and OS
Median follow-up for the SGH cohort of patients with resected
HCC was 2.3 years (IQR, 1.0–4.1 years). Median OS for these
126 patients was 5.4 years, while the median RFS was 2.4 years
(Figure S1). By means of univariable Cox regression analysis,
clinicopathological parameters that shown statistical significant
association with RFS were ALP and PT (p = 0.028 and 0.029
respectively; Table S3). Multivariable analyses continued to show
Serum MCP-1 and Prolactin as HCC Biomarkers
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that RFS was significantly affected by both ALP and PT (p = 0.038
and 0.031 respectively). Factors associating with the OS were
found to be ALP (p = 0.001), PT (p = 0.012), AJCC staging
(p = 0.003) and Childs Pugh scores (p,0.001) by means of
univariable anlaysis (Table S4). However, multivariable analyses
showed that only ALP and PT affected the OS significantly
(p = 0.001 and 0.012 respectively). We found no effect of MCP-1,
prolactin and AFP levels on patient survival. The upper limit of
normal (ULN) values for serum MCP-1 and prolactin were
determined to be 0.62 ng/ml and 83.63 ng/ml respectively. When
these ULN serum levels were used as cut-off values for analysis, we
found that measurement of serum MCP-1 and prolactin levels did
Figure 1. Comparison of serum MCP-1, prolactin and AFP levels in HCC and non-HCC patients. Serum concentrations of (A) MCP-1, (B)
prolactin and (C) AFP in non-HCC chronic hepatitis B carriers (NC group, n = 115) and HCC patients (HCC group, n = 126) in the SGH cohort of patients
were analyzed by multiplex sandwich ELISA (Quantibody Array). Serum MCP-1 concentrations in asymptomatic HBV/HCV carriers (AC group, n = 100),
chronic hepatitis patients with evidence of transaminitis (CH group, n = 101) and HCC patients (HCC group, n = 98) in the MRIN cohort (A) were
analyzed by sandwich ELISA. The boxes represent the central 50% of the data, spanning between the 25th and 75th percentiles and the horizontal line
within each box indicates the median. The cut-off points were: 1.56IQR above 75th percentile (upper limit) and 1.56IQR below 25th percentile (lower
limit). Values beyond the cut-off points were considered as outliers and are represented by the dots. Comparison of biomarker values between
groups was performed using the Mann-Whitney U test.
doi:10.1371/journal.pone.0068904.g001
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not predict RFS (p = 0.7318 and 0.6290 respectively) or OS
outcome (p = 0.3348 and 0.2336 respectively).
Comparison of Diagnostic Sensitivity and Specificity
among MCP-1, Prolactin and AFP
To evaluate the diagnostic values of serum MCP-1 and
prolactin in distinguishing HCC patients from non-HCC hepatitis
B carriers in comparison with serum AFP, we performed the ROC
curve analysis to determine the sensitivity and specificity of these
three markers in the SGH cohort. The area under the ROC curve
(AUC) for MCP-1, prolactin and AFP were calculated to be 0.823
(IQR, 0.766–0.879), 0.820 (IQR, 0.766–0.874) and 0.942 (IQR,
0.908–0.975) respectively (Figure 2). The AUC of AFP was
significantly higher than both MCP-1 (p = 0.0004) and prolactin
(p = 0.0002; figure not shown). Univariable logistic regression
analysis also showed that the higher the values of MCP-1,
prolactin and AFP, the higher the possibility of the subject having
HCC, while multivariable analysis of these markers further
showed that all three affected the risk of having HCC simulta-
neously (Table S5). Based on the ROC analysis, the optimal cut-
off values and the corresponding sensitivity and specificity for AFP,
MCP-1 and prolactin were calculated. At a cut-off value of
0.39 ng/ml for MCP-1, a 73.1% sensitivity and 80.9% specificity
was achieved. The optimal cut-off value for prolactin was reached
at 39.9 ng/ml with 77.3% sensitivity and 70.9% specificity. At the
commonly adopted cut-off value of 20 ng/ml for AFP, its
sensitivity and specificity were 52% and 100% respectively in
the SGH cohort. Surprisingly, the optimal cut-off value for AFP in
this cohort was determined to be 4.0 ng/ml, with 89.9% sensitivity
and 92.7% specificity.
As the clustering of these factors showed a strong correlation
between prolactin and AFP, the ability of discriminating HCC
patients from non-HCC HBV carriers was superior when the
combination of MCP-1 and AFP was used (AUC = 0.974;
Figure 2A), compared to MCP-1+prolactin (AUC = 0.914; not
shown). Therefore, our final diagnostic model included
AFP+MCP-1 only, which was significantly superior to AFP
(p = 0.0242) or MCP-1 (p,0.0001) alone for HCC detection
(Figure 2). The probability of HCC detection using the
AFP+MCP-1 model was calculated using the formula:
P~
e6:12|MCP-1½ z6:41|log AFP½ {7:11
1ze6:12|MCP-1½ z6:41|log AFP½ {7:11
The optimum cut-off P-value was then determined. At the
optimum cut-off P-value of $0.29 (such as at cut-off values of
4 ng/ml AFP +0.4 ng/ml MCP-1), the proposed AFP+MCP-1
model achieved a more favourable 94.1% sensitivity compared to
AFP alone’s 89.9% at the same 92.7% specificity for HCC
detection. Calibration of this model by means of bootstrapping
using 200 samples showed that the predicted probability of HCC
was lower than the actual probability of HCC occurrence
(Figure 3). Compared to our final model of AFP+MCP-1, the
Adequacy Index was only 78.7% for AFP (p,0.001) and 44.1%
for MCP-1 alone (p,0.001, Table 3). Log likelihood ratio tests
showed that the addition of MCP-1 to the AFP model improved its
diagnostic value in discriminating HCC patients from non-HCC
HBV carriers, and vice versa (Table 3).
Discussion
HCC is a heterogeneous neoplasm with an overall poor
prognosis. Currently, measurement of serum AFP and abdominal
ultrasound examination are routinely used as screening tools for
the early detection of HCC in chronic liver disease patients [6].
There have been many studies which suggest survival advantage
and cost effectiveness of early HCC diagnosis and treatment
[5,6,28,29]. Yang et al showed that screening the high-risk
population, such as patients with hepatitis B and C, with a serum
AFP test and real-time ultrasound examination can detect HCC in
the early stages, increasing the resection rate and prolonging the
survival time [28]. Nevertheless, the accuracy and usefulness of
serum AFP and ultrasound liver have their own limitations. Thus
there is a real need to identify reliable biomarkers with higher
degree of sensitivity and specificity for early detection of HCC.
Early biomarker discovery methods involved protein separation-
based approaches, most frequently gel-based techniques such as
two-dimensional polyacrylamide gel electrophoresis (2-D-PAGE).
However the classical 2-D electrophoresis approach has compa-
rably low sensitivity, especially in detecting low abundance
proteins, and requires large amounts of tissue samples as well as
subsequent labour-intensive procedures to optimally identify the
biomarker. These techniques have evolved with the use of mass
spectrometry, which allows the identification of many proteins
with high sensitivity, although the sensitivity decreases with
increased complexity of the samples. Mass spectrometry allows
the relative comparison of proteins in different samples but the
method is not quantitative. In recent years, techniques such as
matrix-assisted laser desorption/ionization (MALDI) and surface-
enhanced laser desorption ionization (SELDI) that later incorpo-
rated time-of-flight (TOF) mass spectrometry have achieved high
resolution profiling. However, despite the significant increase in
throughput and sensitivity, they do not eliminate the need for
extensive subsequent procedures to definitively identify the
differentially expressed protein/peptides in tumor tissues or serum
[24,30].
The ELISA-based proteomics platform is considered by some to
be the most versatile ‘‘omics’’ method for biomarker discovery
[24]. However, it is limited by the availability of well-validated
antibodies [31]. This requirement also makes it ill-suited for
detecting modulations of uncharacterized proteins. However, the
recent advancement in protein microarrays has now given the
ELISA-based approach the capacity for high-throughput and
improved sensitivity. By adopting such platform to screen for
potential serum markers, we identified 113 potential serum
markers that were significantly modulated between HCC and
control groups. Upon validation by ELISA quantification of five
selected markers, we identified two novel markers, namely MCP-1
and prolactin, to be significantly elevated in sera of HCC patients
who were eligible for potentially curative measures such as
Table 2. Correlation between serum markers estimated by
Spearman’s rank correlation coefficient, rho (n = 241).
MCP-1 Prolactin AFP AST ALT
MCP-1 20.2689 0.0244 0.0699 0.0809
Prolactin 0.0024 0.0431 0.0324 20.0621
AFP 0.7926 0.6419 0.1838 20.0319
AST 0.4387 0.7201 0.0444 0.6498
ALT 0.3697 0.4918 0.7291 ,0.0001
*The upper part are the Spearman’s rank correlation coefficients, rho; the lower
part are the p-values of the Spearman’s rank correlation test.
doi:10.1371/journal.pone.0068904.t002
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resection or liver transplant. The significant elevation in serum
levels of these two markers in resectable HCC patients suggests
their potential role as biomarkers in augmenting diagnosis and
surveillance of HCC in at-risk patients. To the best of our
knowledge, this is the first time that the RayBioH L-Series 507
Antibody Array has been used to identify potential cancer
biomarkers, and that has been validated by multiplex sandwich
ELISA arrays.
The finding of significant correlation between serum AFP and
MCP-1 as well as prolactin in our SGH cohort suggested a
possible synergistic mechanism of action and oncogenic pathways
in HCC or in/with its surrounding microenvironment. Further-
more, our result reflected no correlation between serum concen-
trations of MCP-1 and prolactin with other clinicopathological
features in the HCC patients, including liver cirrhosis, portal vein
thrombosis, viral hepatitis status, BCLC stage, and gender. Hence
it is unlikely that MCP-1 and prolactin are surrogate serum
markers for these factors and more likely to be HCC-specific in the
resectable HCC patients.
We next investigated the diagnostic capabilities of MCP-1 and
prolactin by performing ROC analysis and comparing the
resulting AUC with that of AFP in the SGH cohort. Our result
showed that although all three markers were sufficiently compe-
tent (AUC .0.8), neither MCP-1 (AUC = 0.823) nor prolactin
(AUC = 0.820) on their own performed better than AFP alone
(AUC = 0.942). Most studies adopted a cut-off value of 20 ng/ml
for AFP, which gave lower sensitivity and/or specificity especially
in HCCs smaller than 5 cm [32]. In this study, our finding of
4 ng/ml as the optimum cut-off level for AFP in our local
population, a value that is well within the normal range, further
emphasized the inadequacy of using AFP alone for HCC diagnosis
in its current form. Furthermore there is also wide overlapping
between HCC and chronic liver disease. The individual marker’s
limitation in the sensitivity and specificity could be overcome with
the use of combinations of biomarkers. We therefore tested
different combinations of these three markers and successfully
identified a combination, AFP+MCP-1, that showed significantly
superior diagnostic ability than AFP alone (AUC = 0.974 versus
0.942, p = 0.0242). With AFP known to have a significantly lower
positive predictive value in viral-related HCC than non-viral HCC
[33], it is important to establish biomarkers for better surveillance
and detection of virally-related HCC in at-risk individuals,
especially in China and most of Asia, where Hepatitis B is the
predominant aetiology for HCC. Pending confirmation by further
prospective study, we propose that the AFP+MCP-1 model may
answer that need.
Following our identification of the AFP+MCP-1 model, we
proceed to confirm our observation of significantly elevated serum
Figure 2. Receiver Operating Characteristic (ROC) curves. ROC curves of different models for the SGH cohort were generated,
based on samples whose MCP-1, prolactin and AFP values were available (120 HCC and 110 non-HCC controls). Upon comparison, the
AFP+MCP-1 combination (A; AUC= 0.9735) showed significantly improved sensitivity and specificity compared to AFP alone (B; AUC=0.9415,
p = 0.0242) and MCP-1 alone (C; AUC=0.8225, p,0.0001).
doi:10.1371/journal.pone.0068904.g002
Serum MCP-1 and Prolactin as HCC Biomarkers
PLOS ONE | www.plosone.org 7 July 2013 | Volume 8 | Issue 7 | e68904
MCP-1 level in HCC patients by performing sandwich ELISA
analysis of serum MCP-1 levels in a separate and independent
cohort of Indonesian patients from MRIN that included 98
patients with HCC, 101 patients with chronic hepatitis B or C,
and 100 asymptomatic HBV/HCV carriers. The findings were
consistent with our initial results. Due to the use of different
ELISA techniques in quantifying serum MCP-1 levels in our two
patient cohorts, we compared the serum MCP-1 levels in the non-
HCC hepatitis virus carrier groups of both SGH and Indonesian
cohorts, which represented the baseline levels that were least likely
to be influenced by any clinicopathological conditions. We
hypothesized that for a serum marker that was independent of
clinicopathological parameters other than HCC status, MCP-1
levels in the control groups should be consistent between the two
cohorts. Therefore, MCP-1 levels detected by different methods
but with similar sensitivity should not be significantly different.
The result showed that the levels detected by the two different
ELISA methods (median levels of 0.302 ng/ml in the SGH cohort
versus 0.281 ng/ml of the MRIN cohort) were comparable and
robust, with a p-value of 0.552.
The value of diagnostic biomarkers would be enhanced if they
also possess prognostication value. We therefore investigated the
potential of adopting serum MCP-1 and prolactin as prognostic
biomarkers by analysing for their associatuion with patients’ RFS
and OS. Our result showed no correlation between these markers
and both RFS and OS. Neither did we observe correlation
between serum AFP values and both RFS and OS. This result is
consistent with the findings by other groups, thus reiterating the
limitation of AFP as a prognostic HCC biomarker [10,34].
Our finding also suggests the involvement of MCP-1 and
prolactin in the development of HCC. Elevated serum MCP-1 as a
cancer diagnostic marker has been suggested for other malignan-
cies, such as in pancreatic [35] and ovarian [36] cancers.
However, MCP-1 may also be downregulated in certain cancers,
as observed in a Japanese study in gastric cancer [37].
Inflammation caused by innate immune cells has been recognized
as one of the hallmarks of cancer development [38]. Since MCP-1
is a member of the small inducible gene (SIG) family, and plays a
role in the recruitment of monocytes to sites of injury and
infection, its expression may plausibly be associated with HCC
development. There are several studies showing that MCP-1
expression is associated with HCC progression [39]. While
association between MCP-1 and liver damage has been implied
due to the findings that specific non-malignant cells are major
source of MCP-1, such as the hepatic stellate cells that are known
to be involved in the development of fibrosis and cirrhosis [40,41],
such MCP-1 expression occurs during more profound acute liver
injury [42,43]. In an earlier study of a cohort of alcoholic liver
disease patients, it was shown that serum MCP-1 level was only
significantly elevated in severe alcoholic hepatitis patients relative
to that of healthy controls, mild alcoholic hepatitis and inactive
cirrhosis patients [44]. Only an insignificant increasing trend was
observed among the healthy controls, inactive cirrhosis and mild
alcoholic hepatitis patient groups. In our own cohort of resectable
HCC patients, although cirrhosis was seen in 44.4% of the HCC
group, majority of the HCC patients had Child-Pugh class A score
(98.4%) to suggest the presence, if any, of only minimal or mild
liver inflammation and thus no significant activation of the hepatic
stellate cells. Even so, the MRIN data also demonstrated that
serum samples of patients without HCC but with hepatitis showed
only an insignificant increasing trend in serum MCP-1 levels
compared to the asymptomatic hepatitis B or C virus carriers
without active hepatitis (p = 0.194). On the other hand, it is also
known that in HCC, HCC cells and cancer-associated fibroblasts
are prominent contributors of MCP-1, regardless of whether the
liver is cirrhotic or the hepatitis status [45,46]. Therefore, the
elevated serum MCP-1 levels in the HCC patients in this project
were likely to be predominantly expressed by HCC tumors and
the HCC-associated cells, thus showing no significant correlation
with the other liver function parameters. Taken together, MCP-1
is likely involved in the HCC oncogenic process and is produced
either from the tumor itself or from the surrounding stroma.
Elevation of serum prolactin, on the other hand, had also been
observed in other malignancies and explored for their potential as
diagnostic biomarkers, such as in lung and ovarian cancers [47–
51]. However, although shown to be potentially useful as a
member of multi-marker diagnostic panels, none of these studies
could establish prolactin as an independent cancer marker.
Likewise, we observed significant elevation of serum prolactin
level in HCC patients but failed to establish it as an independent
diagnostic HCC biomarker. Studies in the rat model had shown
that prolactin promoted HCC progression while prolactin
inhibition led to reduced tumor growth and longer latency [52].
Furthermore, HCC is known to highly express prolactin receptors
[53]. A recent study reported by Yeh et al provides evidence that
Figure 3. Calibration of the MCP-1+AFP diagnostic model.
Calibration of the AFP+MCP-1 diagnostic model performed via boot-
strapping using 200 samples. The predicted probability of HCC was
found to be lower than the actual probability of HCC occurrence.
doi:10.1371/journal.pone.0068904.g003
Table 3. Comparison of the Adequacy Index and Log
Likelihood ratios of diagnostic models.
Model AUC p-value Likelihood
Adequacy
Index
AFP+MCP-1 0.974 228.36 100.0%
AFP 0.942 ,0.001 179.69 78.7%
MCP-1 0.820 ,0.001 100.67 44.1%
doi:10.1371/journal.pone.0068904.t003
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prolactin may promote HCC progression through the activation of
the Janus kinase 2 pathway upon binding to its receptor [54].
In conclusion, we have found significantly elevated serum MCP-
1 and prolactin in HCC patients and identified serum MCP-1 as a
promising and potentially complementary biomarker with AFP
that may offer more effective early detection of HCC. Upon
further validation in larger sample size studies, measurements of
their serum levels by ELISA, in particular the combination of
MCP-1 and AFP, could prove to be a cheap, rapid, accessible and
user-friendly method of better detection, especially in developing
countries. This will potentially further lessen the huge burden of
care of especially advanced HCC patients globally.
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